Hikma Pharmaceuticals【HIK】銘柄情報 | ADVFN

US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
イギリス
LSE
Hikma Pharmaceuticals Plc (HIK) 銘柄情報

Hikma Pharmaceuticals Plc (HIK)

1,934.00

-20.00

(-1.02%)

終了 12月15日 1:30AM

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

1,934.00

買値

1,925.00

売値

1,926.00

出来高

145,039

1,919.00 日の範囲 1,956.00

1,722.00 52 週間の範囲 2,165.00

時価総額

前日終値

1,954.00

始値

1,955.00

時刻

最終取引時間

財務取引量

2,806,222p

VWAP

1,934.8048

平均取引量 (3 か月)

425,857

発行済株式数

221,886,453

配当利回り

5.15%

PER

22.25

1 株当たり利益 (EPS)

0.87

歳入

2.88B

純利益

192M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.hikma.com

本社

London, Gbr

設立

-

Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the ロンドン証券取引所 with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,954p. Over the last year, Hikma Pharmaceuticals shares have traded in a share price range of 1,722.00p to 2,165.00p.

Hikma Pharmaceuticals currently has 221,886,453 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £4.34 billion. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 22.25.

Hikma Pharmaceuticals Plc Outcome of Audit Tender Process

Hikma Pharmaceuticals Plc 07 November 2024 Hikma Pharmaceuticals PLC Outcome of Audit Tender Process LONDON, 7 November 2024 - Hikma Pharmaceuticals PLC ('the Company' or 'Hikma...

Hikma Pharmaceuticals reiterates full-year guidance amid strong growth

Hikma Pharmaceuticals PLC on Thursday said it is on track to deliver "another strong performance" following trading t ...

Hikma Pharmaceuticals Plc Trading Statement

Hikma Pharmaceuticals Plc 07 November 2024 Hikma continues strong strategic execution and reiterates guidance London, 7 November 2024 - Hikma Pharmaceuticals PLC (Hikma, Group), the...

Hikma Pharmaceuticals Plc 2024 Annual General Meeting Update Statement

Hikma Pharmaceuticals Plc 24 October 2024 Hikma Pharmaceuticals PLC 2024 Annual General Meeting Update Statement LONDON, 24 October 2024 - Hikma Pharmaceuticals PLC ('Hikma' or 'the...

Hikma Pharmaceuticals Plc Block listing Interim Review

Hikma Pharmaceuticals Plc 01 October 2024 Hikma Pharmaceuticals PLC Block Listing Six Monthly Return Date: 1 October 2024 Name of applicant: Hikma Pharmaceuticals PLC Name of scheme:...

Hikma Pharmaceuticals Plc Director/PDMR Shareholding

Hikma Pharmaceuticals Plc 24 September 2024 Hikma Pharmaceuticals PLC (the "Company") LONDON, 24 September 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI:...

Hikma Pharmaceuticals completes acquisition of Xellia's FDF business

Hikma Pharmaceuticals PLC announced on Tuesday it has completed its acquisition of the US finished dosage form busine ...

Hikma Pharmaceuticals Plc Hikma completes Xellia acquisition

Hikma Pharmaceuticals Plc 10 September 2024 Hikma completes Xellia acquisition London, 10 September 2024 - Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group...

Hikma Pharmaceuticals Plc Outcome of Audit Tender Process

Hikma Pharmaceuticals Plc 07 November 2024 Hikma Pharmaceuticals PLC Outcome of Audit Tender Process LONDON, 7 November 2024 - Hikma Pharmaceuticals PLC ('the Company' or 'Hikma...

Hikma Pharmaceuticals reiterates full-year guidance amid strong growth

Hikma Pharmaceuticals PLC on Thursday said it is on track to deliver "another strong performance" following trading t ...

Hikma Pharmaceuticals Plc Trading Statement

Hikma Pharmaceuticals Plc 07 November 2024 Hikma continues strong strategic execution and reiterates guidance London, 7 November 2024 - Hikma Pharmaceuticals PLC (Hikma, Group), the...

Hikma Pharmaceuticals Plc 2024 Annual General Meeting Update Statement

Hikma Pharmaceuticals Plc 24 October 2024 Hikma Pharmaceuticals PLC 2024 Annual General Meeting Update Statement LONDON, 24 October 2024 - Hikma Pharmaceuticals PLC ('Hikma' or 'the...

Hikma Pharmaceuticals Plc Block listing Interim Review

Hikma Pharmaceuticals Plc 01 October 2024 Hikma Pharmaceuticals PLC Block Listing Six Monthly Return Date: 1 October 2024 Name of applicant: Hikma Pharmaceuticals PLC Name of scheme:...

Hikma Pharmaceuticals Plc Director/PDMR Shareholding

Hikma Pharmaceuticals Plc 24 September 2024 Hikma Pharmaceuticals PLC (the "Company") LONDON, 24 September 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI:...

Hikma Pharmaceuticals completes acquisition of Xellia's FDF business

Hikma Pharmaceuticals PLC announced on Tuesday it has completed its acquisition of the US finished dosage form busine ...

Hikma Pharmaceuticals Plc Hikma completes Xellia acquisition

Hikma Pharmaceuticals Plc 10 September 2024 Hikma completes Xellia acquisition London, 10 September 2024 - Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-6	-0.309278350515	1940	1995	1919	389474	1951.93250237	DE
4	140	7.80379041249	1794	1995	1783	414806	1930.79211634	DE
12	-14	-0.718685831622	1948	2022	1757	425857	1890.95514898	DE
26	-76	-3.78109452736	2010	2090	1757	378056	1912.74647982	DE
52	187	10.7040641099	1747	2165	1722	421682	1906.32566258	DE
156	-294	-13.1956912029	2228	2275	1174.5	565363	1786.62737375	DE
260	44.5	2.35512040222	1889.5	2766	1174.5	595415	2026.7671288	DE

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
PPSProton Motor Power Systems Plc	0.55p (83.33%)	5.86M
CADCadogan Energy Solutions Plc	4.25p (77.08%)	14.62M
KZGKazera Global Plc	1.525p (35.56%)	89.49M
WEBWebis Holdings Plc	0.125p (19.05%)	4.67M
PETPetrel Resources Plc	1.35p (17.39%)	1.43M
MILAMila Resources Plc	0.35p (-30.00%)	33.37M
IPXImpax Asset Management Group Plc	250.00p (-23.66%)	3.14M
RNEPEcofin U.s. Renewables Infrastructure Trust Plc	26.20p (-19.88%)	21.5k
PMPPortmeirion Group Plc	174.00p (-15.12%)	58.93k
ROCKRockfire Resources Plc	0.165p (-13.16%)	190.11M
NTVONativo Resources Plc	0.0024p (0.00%)	967.12M
TRPTower Resources Plc	0.027p (1.89%)	481.24M
VRSVersarien Plc	0.034p (11.48%)	374.02M
ORCPOracle Power Plc	0.0315p (-11.27%)	305M
CPXCap-xx Limited	0.145p (0.00%)	260.82M

Oleblue

Oleblue 58秒前

Palantir Will Hit $500 Said By Dan Ives

https://youtu.be/eItyLEJ5_Xc

https://api.wsj.net/api/kaavio/charts/big.chart?nosettings=1&symb=pltr&uf=32&type=4&size=4&sid=206708234&style=330&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1989816315&compid

Dodger1

Dodger1 2分前

Whiskey Whiskers....I like looking at this Live as Bitcoin is owned...and now Gold Backed Decentralized Currency....true value...

Go $AABB

tabbycat

tabbycat 3分前

You are welcome and yes I did see YBYRA did mention preferreds and that they will be offered to current shareholders. I also saw this letter as of August 2024-

Fai 2

Was that 8000 shares buy lmaooo $24 lolll oh my

JSmith5

JSmith5 8分前

People pay a lot more for dividend paying issues.

Definitely. I think that, preconservatorship, the GSEs were regarded as an old people stock like the electric company or even close to Treasuries. So all this speculation about releasing them as more like utilities is not some genius

nowwhat2

nowwhat2 10分前

These are a few of the things I've been monitoring and it's been almost just these few things.....
COULD include Solana and Doge as well, but it's been basically just these few levels.
Why, just they in themselves have offered up tons of entertainment !.......LoLoL !

h

pitcook

pitcook 10分前

For all the shareholders who are clueless of what is more important, the share price going up and making a profit on your investment or we won a major award!

LWLG technology that just won the most coveted Industry Award for Optical Integration the last 2 years in a row

axelvento

axelvento 10分前

Mitch McConnell warns RFK Jr. against effort to undermine polio vaccines

"Anyone seeking the Senate's consent to serve in the incoming Administration would do well to steer clear of even the appearance of association with such efforts," McConnell said in a statement.

"T

stockinspector

stockinspector 12分前

Why do you waver in your decision is the question. I haven't changed since I decided to buy in.

chazzy1

chazzy1 14分前

Congratulations DB! I think that you just hit the ball out of the park. Your summary of where we are, combined with your rhetorical (what if) projections of where we could easibly be headed, present a reasonable basis for optimism. Ray Leon is certainly real, yet his resume is more like, fantastic.

theswordman

theswordman 16分前

Sorta surprised you still show up/post. After you and buddy/mountain/ monroe/2012/chuckles (your hero) and the ms sooey told us for years about the SEC and DOJ investigations and how nodder did NOTHING wrong--all this legal investigation was about 13D and shorts.

Remember your versio

Kool Aid Man

Kool Aid Man 18分前

Attorney disagrees...CEO apparently issued 844,200,000 shares into the O/S since the attorney wrote this opinion report on 10/17/24--The Company has (a) 5,000,000,000 (Five Billion) authorized shares of common stock, of which 2,256,709,801 shares of common stock are issued >>as of the date of thi

OMOLIVES

OMOLIVES 18分前

You kids....:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175521920

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175491976

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175472891

https:/

bluebird50

bluebird50 19分前

bluebird50

bluebird50 21分前

Bill.... Shares are Held Tightly like Bangkok paid employee....

I think you're a fictual character.... but if in the event you're not! I would love to meet you and hang out sometime!!!! Che che che! Hang 3.....che che che...

Hawk05

Hawk05 21分前

https://www.optimumpetvitality.com/learn-go-with-dr-laurie/pemf-therapy-for-dogs

firebag1

firebag1 22分前

Sounds good. Ty

NY1972

NY1972 26分前

Why bother with CARNK after they licensed 1xx from MSK. CAR T 1xx lowers the activation and energy req'd to survive in the hypoxic TME. More durable and lower CRS CART therapy will beat ADC in terms of AE and OS long term.

dstock07734

dstock07734 26分前

Horse,

I keep in mind the name of the coffee. Definitely will give it a try.

CaptPete1776

CaptPete1776 27分前

Phase 2 trial data due this month and a decision on Dec 27 on who wins the funding bid to acquire the parent company in South Korea.

Cornerstone_Marketing

Cornerstone_Marketing 27分前

Incredible podcast!!

https://x.com/adia_nutrition/status/1868069359668891790?s=46&t=ZV-JoM4olm35bFSad3ozrw

I ll be back

I ll be back 27分前

Welcome Back!
Kind of thought you would show up this weekend. 🤠

Hikma Pharmaceuticals

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約